Panel Discussion: Advancing Drug Development in Cardiovascular-Kidney-Metabolic (CKM) Syndrome

• Explore our evolving understanding of the pathophysiology linking cardiovascular, kidney and metabolic disorders
• Identify when and how overlapping CKM phenotypes can be leveraged to design more efficient clinical trials
• Discuss next steps in integrated drug development and regulatory frameworks for CKM components with shared mechanistic drivers

Speakers:

Matthias Kretzler

Professor of Medicine

University of Michigan

Aliza Thompson

Director of the Division of Cardiology and Nephrology, Center for Drug Evaluation

FDA

Joseph Kupferman

Global Clinical Head

AstraZeneca

Pablo Cabral

Executive Director External Innovation

Eli Lilly & Co.